These data support an effect of IL-13 to decrease total and reduced GSH through high 15LO1, PEBP1, and GPX4 activity, which is partially compensated by (a) increased expression/activity of SLC7A11 to enhance new intracellular GSH production and (b) increased export of GSSG
My Thoughts I love this to biiiiits
These approaches have led to significant weight loss with the dual GLP-1/glucagon receptor agonist survodutide (-13.5% with the 6-mg dose at 76 weeks in a phase 3 SYNCHRONIZE-1 trial) [16] , the dual GLP-1 receptor agonist and GIP antagonist Maridebart cafraglutide (known as MariTide) (-12.3% to -16.2% across different doses at 52 weeks in a phase 2 trial) [17] or the triple GLP-1/GIP/glucagon receptor agonist retatrutide (-24.2% with the 12-mg dose at 48 weeks in a phase 2 trial) [18]
Aboukhater D, Morad B, Nasrallah N, Nasser SA, Sahebkar A, Kobeissy F, Boudaka A, Eid AH
Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Human IL4
